Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 10/3/2024 | Perform | Oppenheimer | |
| 9/4/2024 | $46.00 | Overweight | Piper Sandler |
| 3/21/2024 | $45.00 | Outperform | Raymond James |
| 1/31/2024 | $37.00 | Market Perform | BMO Capital Markets |
| 12/8/2023 | $58.00 | Overweight | Wells Fargo |
| 12/8/2023 | Overweight | Wells Fargo | |
| 11/7/2023 | $42.00 | Buy | Citigroup |
144 - BridgeBio Pharma, Inc. (0001743881) (Subject)
8-K - BridgeBio Pharma, Inc. (0001743881) (Filer)
144 - BridgeBio Pharma, Inc. (0001743881) (Subject)
4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)
SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)
SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)
Scotiabank initiated coverage of BridgeBio Pharma with a rating of Sector Outperform
Oppenheimer initiated coverage of BridgeBio Pharma with a rating of Perform
Piper Sandler initiated coverage of BridgeBio Pharma with a rating of Overweight and set a new price target of $46.00
4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D., has been appointed President and Chief Operating Officer (COO) of the company. Dr. Trimarchi will assume his new responsibilities effective immediately and will continue to report directly to CEO and founder, Neil Kumar, Ph.D. In this newly created position, Dr. Trimarchi will be responsible for driving operational excellence, strategic planning, and overall business success at BridgeBio. He will lead cross-functional activities to develop a centralized ope
The oversubscribed financing was led by Cormorant Asset Management and co-led by Omega Funds with participation from affiliates of Deerfield Management, GV (Google Ventures), EcoR1 Capital, Wellington Management, Enavate Sciences, Surveyor Capital (a Citadel company), Aisling Capital, Casdin Capital, and Longwood FundThis capital raise provides BBOT with runway to achieve significant clinical inflection points over the next 18-24 months as it progresses multiple assets into the clinic to treat patients with a wide variety of RAS and PI3Kα pathway malignancies PALO ALTO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commerci
PALO ALTO, Calif., Oct. 25, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that it has added a new independent director to its board: Hannah Valantine, M.D., a national leader in organ transplant genomics who led the National Institutes of Health's efforts to promote diversity, equity, and inclusion in biomedical research. Dr. Valantine currently serves as a professor of medicine at Stanford University School of Medicine, where she has been a faculty member since 1987. Dr. Valantine was elected to the National Academy of Medicine in 2020 for her research in organ transplantation
- In Cohort 5 of PROPEL 2 (0.25 mg/kg/day), oral treatment with infigratinib resulted in a statistically significant and sustained increase in annualized height velocity (AHV), with a mean change from baseline of +2.51cm/yr at Month 12, and +2.50 cm/yr at Month 18 (p=0.0015) - At Month 18, there was a statistically significant improvement in body proportionality (p-value of 0.001). The mean upper to lower body segment ratio was 1.88 at Month 18, as compared to 2.02 at baseline - Infigratinib continues to be well-tolerated as a single daily oral therapy with no adverse events (AEs) assessed as treatment-related in any participant in Cohort 5 - PROPEL 3, the global Phase 3 registrational s
- Acoramidis treatment resulted in increased serum transthyretin (TTR) levels by Day 28 that were sustained and were correlated with a reduced risk of all-cause mortality (ACM), cardiovascular mortality (CVM), and cardiovascular-related hospitalization (CVH) in ATTR-CM participants through month 30 - Acoramidis treatment resulted in a significant improvement in the composite endpoint of CVM and CVH in ATTR-CM participants, with benefit evident as early as Month 3 - In ATTRibute-CM, participants with at least one CVH had a significantly higher risk of mortality, highlighting the need for ATTR-CM treatments that reduce risk of CVH - BridgeBio also shared the rationale and design of ACT-EAR
- BridgeBio to host investor call on Wednesday, May 29, 2024 at 5:30 pm ET, with presentations from Mathew Maurer, M.D. of Columbia University Irving Medical Center, U.S. and Ahmad Masri, M.D., M.S. of Oregon Health & Science University, U.S. PALO ALTO, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that 12 oral and moderated poster presentations will be shared at the 2024 International Symposium on Amyloidosis (ISA), taking place in Rochester, Minnesota on May 26 - 30, 2024. BridgeBio will also host an investor call on May 2
- Acoramidis demonstrated the earliest known time to separation in cardiovascular outcomes in the ATTRibute-CM study (3 months), with statistically significant risk reduction of 36% on All-Cause Mortality (ACM) alone at Month 36 within the Open Label Extension - The continued curve separation of the composite endpoint of ACM and recurrent cardiovascular-related hospitalizations (CVH) emphasizes the importance of early intervention resulting in early and sustained clinical benefits, with acoramidis demonstrating 46% (p<0.0001) and 48% (p<0.0001) reductions in the composite endpoint of ACM and recurrent CVH at Months 36 and 42, respectively - The preliminary results from this ongoing OLE st
- In Cohort 5 of PROPEL 2, daily oral treatment of infigratinib at 0.25mg/kg resulted in statistically significant and sustained increases in annualized height velocity (AHV), with a mean change from baseline of +2.50cm/year at Month 18 (P=0.001) - Data also presented at European Society of Paediatric Endocrinology on November 18th at 10 am GMT - To date, infigratinib has received Breakthrough Designation from the U.S. Food and Drug Administration for achondroplasia, as well as Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation - PROPEL 3, the global Phase 3 registrational study of infigratinib in achondroplasia, continues to enroll on schedule, with e
- Patients on acoramidis, a near complete (≥90%) TTR stabilizer in clinical development, lived longer and better as shown in the ATTRibute-CM study. This is the only Phase 3 study of an ATTR-CM disease-modifying treatment to demonstrate improvement in hard clinical outcomes in the combined assessment of CVH and ACM to this degree, this quickly - BridgeBio's late-stage pipeline continues to rapidly progress with three Phase 3 readouts expected in 2025. Program highlights from this quarter include: - CALIBRATE, the Phase 3 clinical trial of encaleret in ADH1, completed screening - FORTIFY, the Phase 3 clinical trial for LGMD2I/R9, completed enrollment - The FDA granted Break
Cantor Fitzgerald analyst Josh Schimmer reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and maintains $70 price target.
B of A Securities analyst Geoff Meacham maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and lowers the price target from $50 to $42.